Daily Cosmetic Research Analysis
Across cosmetic dermatology, a randomized clinical trial shows a niacinamide + 2-mercaptonicotinyl glycine dermocosmetic routine achieves melasma control comparable to Kligman triple regimen with better tolerance. A large retrospective series supports fully ablative CO2 laser as a durable option for rhinophyma with low recurrence. A phase 2 randomized comparison suggests ruxolitinib cream matches or exceeds mid-potency corticosteroid efficacy with faster itch relief in mild–moderate atopic derma
Summary
Across cosmetic dermatology, a randomized clinical trial shows a niacinamide + 2-mercaptonicotinyl glycine dermocosmetic routine achieves melasma control comparable to Kligman triple regimen with better tolerance. A large retrospective series supports fully ablative CO2 laser as a durable option for rhinophyma with low recurrence. A phase 2 randomized comparison suggests ruxolitinib cream matches or exceeds mid-potency corticosteroid efficacy with faster itch relief in mild–moderate atopic dermatitis.
Research Themes
- Melasma management with dermocosmetics versus standard triple therapy
- Energy-based device therapy for cosmetic rhinophyma
- Steroid-sparing topical JAK inhibition in mild–moderate atopic dermatitis
Selected Articles
1. A Novel Dermocosmetic Routine Containing Vitamin B3 and 2-Mercaptonicotinyl Glycine Significantly Improves Melasma After 3 Months of Daily Use.
In a randomized single-blind 6-month trial (n=91), both a niacinamide + 2-mercaptonicotinyl glycine dermocosmetic routine and Kligman triple significantly improved melasma by 3 months, with KT showing an early clinical advantage. After switching, both groups achieved similar MASI reductions by month 6; QoL and skin hydration improved in both, and overall tolerance favored the dermocosmetic regimen.
Impact: This pragmatic randomized study provides head-to-head clinical evidence that a non-HQ dermocosmetic routine can maintain melasma control comparable to KT while improving tolerance, informing long-term maintenance strategies.
Clinical Implications: Consider a niacinamide + 2-mercaptonicotinyl glycine dermocosmetic routine as a steroid/HQ-sparing option for melasma maintenance or in patients intolerant to KT, alongside strict photoprotection.
Key Findings
- Both regimens significantly reduced MASI at 3 months (p<0.05), with an early advantage for KT.
- After switching, MASI reduction at 6 months was similar between the groups (38.1% vs 41.2%).
- Quality of life and skin hydration improved in both groups; overall tolerance favored the dermocosmetic routine.
Methodological Strengths
- Randomized, single-blind design with active comparator and standardized sunscreen use
- Use of validated outcomes (MASI, mMASI, IGA, MELASQOL) over a 6-month period
Limitations
- Single-blind design with potential assessment bias
- Study population limited to women with predominant Fitzpatrick III–IV; generalizability may be limited
Future Directions: Conduct double-blind, multicenter RCTs including diverse skin phototypes, and explore mechanistic biomarkers to optimize sequence or combination strategies (e.g., KT induction followed by dermocosmetic maintenance).
INTRODUCTION: Melasma is a chronic refractory pigmentation disorder. Kligman triple (KT) formula is the gold standard. A dermocosmetic (DC) serum containing vitamin B3 and 2-mercaptonicotinyl glycine has been developed for melasma. This study assessed the benefits of DC serum compared to KT in melasma. MATERIAL AND METHODS: A randomized, single-blind 6-month study was conducted in women with melasma. Subjects were randomized to Group A (morning: serum; evening: cream, for 6 months) or to Group B (1st 3 months: morning: skin hydrating gel; evening: KT, followed by 3 months of DC routine regimen); all subjects applied a sunscreen with an SPF 50+ twice daily. Assessments included MASI, mMASI, IGA, skin hydration, radiance and fine wrinkles, tolerance, and quality of life (QoL) using MELASQOL. RESULTS: Ninety-one women aged 44 ± 6 years of Phototypes III (30%) and IV (36%) were recruited. Both regimens significantly (p < 0.05) improved MASI after 3 months. A clinically relevant difference in favor of KT was observed. Three months after the switch, both Group A (38.1%) and Group B (41.2%) provided a similar significant (p < 0.05) percentage reduction of MASI score, with no between-group difference. The mMASI and IGA showed similar results. QoL and skin hydration significantly (p < 0.05) improved in both groups after 6 months. Skin radiance and fine wrinkles also improved. Global tolerance was better with the DC routine. CONCLUSIONS: Both DC routine and KT significantly improved melasma after 3 months of use. DC further improved melasma when replacing KT for 3 further months, with similar results when used alone for 6 months.
2. Fully ablative CO
In a retrospective cohort of 152 rhinophyma patients (grades I–III) treated with fully ablative CO2 laser, 84% achieved meaningful aesthetic improvement (GAIS ≥3), recurrence was infrequent (4%), and adverse effects were generally mild (hypopigmentation 9%, textural change 2%). A deep learning model highlighted disease grade, age, and phototype as key predictors of outcomes.
Impact: This large real-world series supports fully ablative CO2 laser as a durable, safe option for significant cosmetic deformity due to rhinophyma and introduces predictive analytics to individualize risk and outcomes.
Clinical Implications: For appropriately selected rhinophyma patients, fully ablative CO2 laser can provide high satisfaction and low recurrence, with counseling on mild hypopigmentation risk; patient factors (grade, age, phototype) may guide expectations.
Key Findings
- Meaningful aesthetic improvement (GAIS ≥3) in 84% of patients after fully ablative CO2 laser
- Low recurrence rate of 4%, mainly in older men with grade III rhinophyma
- Adverse effects were generally mild (hypopigmentation 9%, textural changes 2%); predictive modeling identified grade, age, and phototype as key factors
Methodological Strengths
- Large sample size (n=152) reflecting real-world practice
- Use of standardized aesthetic outcome (GAIS) and incorporation of predictive analytics
Limitations
- Retrospective, single-arm design without a control group
- Abstract lacks detailed laser parameters and follow-up duration stratification
Future Directions: Prospective, controlled studies comparing ablative versus non-ablative modalities and external validation of predictive models to personalize treatment planning.
BACKGROUND: Rhinophyma, a progressive nasal deformity resulting from advanced rosacea, presents significant cosmetic and functional challenges. Fully ablative CO OBJECTIVES: To assess the long-term outcomes, safety and patient satisfaction associated with fully ablative CO METHODS: A retrospective study was conducted on 152 patients with rhinophyma (grades I-III) treated with CO RESULTS: Significant aesthetic improvement (GAIS ≥ 3) was observed in 84% of p atients, with an average satisfaction score of 2.51/3. Recurrence was rare (4%), occurring primarily in older men with grade III rhinophyma. Side effects included mild hypopigmentation (9%) and textural changes (2%). A deep learning model identified rhinophyma grade, age and Fitzpatrick phototype as key predictors of treatment outcomes. Logistic regression confirmed that advanced rhinophyma grades significantly reduced hypopigmentation risk [adjusted odds ratio (aOR) 0.43, 95% confidence interval (CI) 0.18-0.97; CONCLUSIONS: Fully ablative CO
3. Ruxolitinib Cream Versus Triamcinolone Cream in Adults With Mild to Moderate Atopic Dermatitis.
In a randomized phase 2 comparison up to week 4, 1.5% ruxolitinib cream outperformed 0.1% triamcinolone on multiple efficacy endpoints in adults with mild–moderate AD, including earlier and greater itch reduction and higher EASI75/EASI90 and IGA 0/1 responses. Safety was favorable with mild to moderate AEs.
Impact: Demonstrates a steroid-sparing, nonsteroidal topical option that can achieve rapid itch control and robust short-term efficacy, addressing a key unmet need in mild–moderate AD management.
Clinical Implications: Ruxolitinib cream may be considered when steroid-sparing or rapid itch relief is desired, with the caveat that evidence here is limited to 4 weeks and adults with longstanding mild–moderate AD.
Key Findings
- Higher EASI75 and EASI90 at week 4 with ruxolitinib vs triamcinolone (56.0% vs 47.1%; 26.0% vs 13.7%)
- More patients achieved IGA 0/1 with ≥2-grade improvement at week 4 (38.0% vs 25.5%)
- Earlier and greater itch improvement (day 2 ≥2-point NRS: 42.5% vs 20.5%, P=0.0412; week 4 ≥4-point NRS: 62.5% vs 32.3%, P=0.0128)
Methodological Strengths
- Randomized active-comparator design within a dose-ranging phase 2 trial
- Multiple clinically meaningful endpoints including early itch NRS changes
Limitations
- Comparative data limited to 4 weeks; long-term durability and safety versus corticosteroids remain unassessed
- Triamcinolone used only for 4 continuous weeks; generalizability beyond mid-potency steroid is unclear
Future Directions: Longer head-to-head trials against various potency steroids and other nonsteroidals, with safety surveillance and patient-reported outcomes to inform chronic use.
Atopic dermatitis (AD), a chronic inflammatory skin disease, is typically treated with topical corticosteroids in patients with mild to moderate disease, creating an ongoing need for nonsteroidal therapies. As part of a phase 2, randomized, dose-ranging study of ruxolitinib (Janus kinase [JAK]1/JAK2 inhibitor) cream, twice-daily 1.5% ruxolitinib cream was compared with twice-daily 0.1% triamcinolone cream (midpotency topical corticosteroid) in adults with mild to moderate AD for ≥2 years. Triamcinolone cream was only used for 4 continuous weeks of the 8-week vehicle-controlled period for safety considerations; thus, data here are reported up to week 4 in the study. At week 4, substantially more patients who applied 1.5% ruxolitinib cream vs 0.1% triamcinolone cream achieved ≥75% or ≥90% improvement from baseline in the Eczema Area and Severity Index (56.0% vs 47.1% and 26.0% vs 13.7%, respectively) and Investigator’s Global Assessment Score of 0/1 with ≥2-grade improvement from baseline (38.0% vs 25.5%). Significantly more patients achieved ≥2-point improvement in itch numerical rating scale (NRS) on day 2 with 1.5% ruxolitinib cream vs 0.1% triamcinolone cream (42.5% vs 20.5% [P=0.0412]), and significantly more patients achieved ≥4-point improvement in itch NRS at week 4 (62.5% vs 32.3% [P=0.0128]). Ruxolitinib cream was well tolerated, with no clinically significant application site reactions. Treatment-emergent adverse events were mild/moderate in severity; nasopharyngitis and headache were most common (n=2 [4.0%] each). In summary, ruxolitinib cream is a well-tolerated nonsteroidal therapy with efficacy at least as good as a midpotency topical corticosteroid while avoiding the potential concerns of long-term corticosteroid use.